Clinical Evaluation of the Sorin Group's REPLY MR-conditional Pacing System
1 other identifier
interventional
N/A
0 countries
N/A
Brief Summary
Permanent cardiac pacemakers have represented a contraindication to Magnetic Resonance Imaging (MRI). Strong static, gradient and radiofrequency fields used for MRI are thought to be detrimental to pacemaker function and possibly cause harm to patients undergoing MRI examinations. A previous study has shown that MRI is indicated in 17% of all patients with pacemakers within 12 months of device placement , which demonstrates the need of practical, safe approach for performing MRI on pacemaker patients. A new Reply MR-conditional pacing system is developed by Sorin Group for safe use in the MRI environment. The new pacing system is composed by the Reply pacemaker and the Filtrea bradycardia pacing leads. This study intends to demonstrate the safety and the efficacy in the MRI environment of the Sorin Group Reply MR-conditional pacing system.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Jan 2012
Shorter than P25 for phase_3
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 1, 2011
CompletedFirst Posted
Study publicly available on registry
April 25, 2011
CompletedStudy Start
First participant enrolled
January 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2013
CompletedJuly 17, 2013
July 1, 2013
1.3 years
April 1, 2011
July 16, 2013
Conditions
Outcome Measures
Primary Outcomes (4)
assess the pacing system-, MRI- and implant procedure-related complication-free rate
1 month
assess atrial and ventricular lead-related complication-free rate
3 months
compare the changes in atrial and ventricular pacing thresholds before and after MRI, between MRI and control groups
3 months
compare the changes in atrial and ventricular sense amplitude after MRI between MRI and control groups
3 months
Secondary Outcomes (3)
Summarize all implant procedure, pacing system- and MRI procedure-related adverse events
12 months
Summarize atrial and ventricular electrical performances
3 months
Summarize atrial and ventricular lead handling
2 weeks
Study Arms (2)
Control
ACTIVE COMPARATORControl
MRI
EXPERIMENTALexperimental
Interventions
Eligibility Criteria
You may qualify if:
- Patients who are candidates for dual-chamber pacemaker primo-implantation
- Patients who have indication for implantation of a dual-chamber pacemaker according to the American College of Cardiology and the American Heart Association
- Patients who are able and willing to undergo elective MRI scanning
- Patients who are scheduled for implant of a Reply DR pacemaker and Filtrea lead(s) only
- Patients who provided signed and dated informed consent
You may not qualify if:
- Non MR-compatible device or material implant
- Chronic atrial fibrillation (for atrial lead evaluation)
- Incessant ventricular tachyarrhythmia (for ventricular lead evaluation)
- Inability to understand the purpose of the study or refusal to co-operate
- Unavailability for scheduled follow-ups at the implanting centre
- Already included in another clinical study that could affect the results of this study
- Inability or refusal to provide informed consent
- Patient is minor (less than 18-year old)
- Patient is pregnant (women of childbearing potential should have a negative pregnancy test prior to enrolment);
- Patient has life expectancy of less than 1 year
- Patient is forfeiture of freedom or under guardianship
- Any patient to whom a contra-indication from device and lead labeling applies
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- LivaNovalead
Study Officials
- PRINCIPAL INVESTIGATOR
Francisco LEYVA, Dr
Queen Elizabeth BIRMINGHAM UNITED KINGDOM
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 1, 2011
First Posted
April 25, 2011
Study Start
January 1, 2012
Primary Completion
May 1, 2013
Study Completion
May 1, 2013
Last Updated
July 17, 2013
Record last verified: 2013-07